Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$32.2 - $42.44 $1.58 Million - $2.08 Million
-49,053 Reduced 87.35%
7,106 $228,000
Q4 2023

Feb 14, 2024

BUY
$31.87 - $40.71 $1.55 Million - $1.98 Million
48,703 Added 653.21%
56,159 $2.28 Million
Q3 2023

Nov 14, 2023

BUY
$34.17 - $42.98 $254,771 - $320,458
7,456 New
7,456 $257,000
Q2 2022

Aug 15, 2022

BUY
$52.3 - $71.59 $217,515 - $297,742
4,159 New
4,159 $232,000
Q1 2022

May 16, 2022

SELL
$51.32 - $68.5 $2.51 Million - $3.36 Million
-49,002 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$47.03 - $57.12 $1.8 Million - $2.18 Million
-38,226 Reduced 43.82%
49,002 $2.7 Million
Q3 2021

Nov 15, 2021

SELL
$52.17 - $70.2 $30,154 - $40,575
-578 Reduced 0.66%
87,228 $4.59 Million
Q2 2021

Aug 16, 2021

SELL
$68.86 - $83.34 $249,410 - $301,857
-3,622 Reduced 3.96%
87,806 $6.05 Million
Q1 2021

May 17, 2021

BUY
$76.15 - $111.94 $504,569 - $741,714
6,626 Added 7.81%
91,428 $7.05 Million
Q4 2020

Feb 16, 2021

BUY
$96.85 - $148.25 $7.11 Million - $10.9 Million
73,460 Added 647.68%
84,802 $8.39 Million
Q3 2020

Nov 16, 2020

BUY
$122.47 - $213.56 $642,232 - $1.12 Million
5,244 Added 86.0%
11,342 $1.61 Million
Q2 2020

Aug 14, 2020

BUY
$185.52 - $231.25 $802,002 - $999,693
4,323 Added 243.55%
6,098 $1.2 Million
Q1 2020

May 15, 2020

SELL
$143.0 - $274.03 $1.28 Million - $2.45 Million
-8,927 Reduced 83.41%
1,775 $348,000
Q4 2019

Feb 14, 2020

SELL
$146.12 - $215.82 $29,516 - $43,595
-202 Reduced 1.85%
10,702 $2.21 Million
Q3 2019

Nov 14, 2019

BUY
$130.44 - $187.64 $1.42 Million - $2.05 Million
10,904 New
10,904 $1.67 Million

Others Institutions Holding GLPG

About GALAPAGOS NV


  • Ticker GLPG
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,835,500
  • Market Cap $1.9B
  • Description
  • Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...
More about GLPG
Track This Portfolio

Track Voloridge Investment Management, LLC Portfolio

Follow Voloridge Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voloridge Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voloridge Investment Management, LLC with notifications on news.